NO974899L - Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog - Google Patents

Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog

Info

Publication number
NO974899L
NO974899L NO974899A NO974899A NO974899L NO 974899 L NO974899 L NO 974899L NO 974899 A NO974899 A NO 974899A NO 974899 A NO974899 A NO 974899A NO 974899 L NO974899 L NO 974899L
Authority
NO
Norway
Prior art keywords
therapeutically active
preparing
analogous process
active aprotinin
aprotinin analog
Prior art date
Application number
NO974899A
Other languages
English (en)
Other versions
NO974899D0 (no
Inventor
Soeren Bjoern
Kjeld Norris
Fanny Norris
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974899(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO974899L publication Critical patent/NO974899L/no
Publication of NO974899D0 publication Critical patent/NO974899D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing Of Solid Wastes (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Particle Accelerators (AREA)

Abstract

Det beskrives nye terapeutisk aktive aprotininanaloger med den generelle formel x4 aprotinin (1-58) hvor X4 representerer en N-cerminalutvidelse med en eller flere aminosyrer.
NO974899A 1989-03-03 1997-10-23 Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog NO974899D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid
PCT/DK1990/000058 WO1990010075A1 (en) 1989-03-03 1990-03-01 Yeast processing system comprising a negatively charged amino acid adjacent to the processing site

Publications (2)

Publication Number Publication Date
NO974899L true NO974899L (no) 1997-10-23
NO974899D0 NO974899D0 (no) 1997-10-23

Family

ID=26065137

Family Applications (2)

Application Number Title Priority Date Filing Date
NO913427A NO304236B1 (no) 1989-03-03 1991-09-02 Polypeptid omfattende en sammensmelting av et signalpeptid, et lederpeptid og et heterologt protein eller polypeptid, DNA-konstruksjoner omfattende en DNA-sekvens som koder for polypeptidet samt gjµrstamme og vektor som kan uttrykke det
NO974899A NO974899D0 (no) 1989-03-03 1997-10-23 Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO913427A NO304236B1 (no) 1989-03-03 1991-09-02 Polypeptid omfattende en sammensmelting av et signalpeptid, et lederpeptid og et heterologt protein eller polypeptid, DNA-konstruksjoner omfattende en DNA-sekvens som koder for polypeptidet samt gjµrstamme og vektor som kan uttrykke det

Country Status (23)

Country Link
US (3) US5395922A (no)
EP (1) EP0461165B2 (no)
JP (1) JP2609367B2 (no)
KR (1) KR970005928B1 (no)
AT (1) ATE110414T1 (no)
AU (1) AU624694B2 (no)
CA (1) CA2050336C (no)
CZ (1) CZ285239B6 (no)
DD (1) DD296965A5 (no)
DE (1) DE69011853T3 (no)
DK (2) DK105489D0 (no)
ES (1) ES2062514T5 (no)
FI (1) FI104985B (no)
HU (2) HU215538B (no)
IE (1) IE66469B1 (no)
IL (1) IL93609A (no)
NO (2) NO304236B1 (no)
NZ (1) NZ232742A (no)
PL (1) PL163532B1 (no)
RU (1) RU2194758C2 (no)
UA (1) UA27706C2 (no)
WO (1) WO1990010075A1 (no)
ZA (1) ZA901476B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
AU647025B2 (en) * 1989-05-19 1994-03-17 Biotechnology Research And Development Corporation Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
JP4275741B2 (ja) 1996-12-13 2009-06-10 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 血小板由来増殖因子タンパク質の分析および分離
JP4187796B2 (ja) * 1996-12-20 2008-11-26 ノボ ノルディスク アクティーゼルスカブ 酵母で発現されたｎ末端伸長タンパク質
JP2001527387A (ja) * 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
EP1049790A1 (en) 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
KR20030004315A (ko) 1999-12-29 2003-01-14 노보 노르디스크 에이/에스 효모에서 개선된 발효 수율을 갖는 인슐린 선구물질 및인슐린 선구물질 유사체의 제조 방법
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ATE492631T1 (de) 2002-09-13 2011-01-15 Cornell Res Foundation Inc Verwendung von mutationen zur verbesserung von aspergillus-phytasen
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
EP1917363B1 (en) 2005-08-16 2011-06-22 Novo Nordisk A/S Method for making mature insulin polypeptides
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) * 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
US8153395B2 (en) 2006-11-22 2012-04-10 Novo Nordisk A/S Method of making activated carboxypeptidases
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
WO2009021955A1 (en) 2007-08-13 2009-02-19 Novo Nordisk A/S Rapid acting insulin analogues
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
RU2514430C2 (ru) 2007-08-15 2014-04-27 Ново Нордиск А/С Аналоги инсулина с ацильной и алкиленгликолевой группировкой
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
KR101702342B1 (ko) * 2009-03-12 2017-02-03 빅텍 프라이빗 리미티드 폴리뉴클레오타이드 및 폴리펩타이드 서열 및 이의 방법
AU2010264636B2 (en) 2009-06-26 2013-06-27 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
ES2550761T3 (es) 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
CN102791730A (zh) 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
JP5931857B2 (ja) 2010-06-23 2016-06-08 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン誘導体
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
CA2821613A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CN103254277B (zh) 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
CN105308067B (zh) 2013-06-07 2020-07-24 诺和诺德股份有限公司 制备成熟胰岛素多肽的方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
EP3268384B1 (en) 2015-03-10 2021-11-03 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
JP2018531901A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
MX2018002223A (es) 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
SG11202001077UA (en) 2017-08-17 2020-03-30 Novo Nordisk As Novel acylated insulin analogues and uses thereof
PE20221260A1 (es) 2019-12-11 2022-08-16 Novo Nordisk As Analogos de insulina novedosos y usos de estos
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
WO1984004330A1 (en) * 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0195680A3 (en) * 1985-03-21 1987-06-10 Immunex Corporation The synthesis of protein with an identification peptide
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
JPH03503596A (ja) * 1987-06-24 1991-08-15 ノボ・ノルディスク　エー／エス 蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HU213571B (en) * 1988-07-23 1997-08-28 Delta Biotechnology Ltd Process for producing peptides and dna sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
IE900749L (en) 1990-09-03
IL93609A0 (en) 1990-12-23
DE69011853T2 (de) 1994-12-15
HU211600A9 (en) 1995-12-28
IL93609A (en) 2001-11-25
DK0461165T3 (da) 1994-11-21
AU5261290A (en) 1990-09-26
NO913427D0 (no) 1991-09-02
RU2194758C2 (ru) 2002-12-20
NO304236B1 (no) 1998-11-16
IE66469B1 (en) 1995-12-27
ZA901476B (en) 1990-11-28
DK105489D0 (da) 1989-03-03
CA2050336A1 (en) 1990-09-04
KR970005928B1 (ko) 1997-04-22
CZ285239B6 (cs) 1999-06-16
UA27706C2 (uk) 2000-10-16
ATE110414T1 (de) 1994-09-15
JP2609367B2 (ja) 1997-05-14
AU624694B2 (en) 1992-06-18
EP0461165A1 (en) 1991-12-18
HU902376D0 (en) 1991-11-28
KR920701452A (ko) 1992-08-11
DE69011853T3 (de) 1998-06-25
NZ232742A (en) 1991-10-25
EP0461165B2 (en) 1998-03-25
DD296965A5 (de) 1991-12-19
NO913427L (no) 1991-11-01
FI104985B (fi) 2000-05-15
EP0461165B1 (en) 1994-08-24
CZ103990A3 (cs) 1999-03-17
NO974899D0 (no) 1997-10-23
PL163532B1 (pl) 1994-04-29
FI914125A0 (fi) 1991-09-02
HU215538B (hu) 1999-01-28
HUT58370A (en) 1992-02-28
WO1990010075A1 (en) 1990-09-07
JPH04504846A (ja) 1992-08-27
US5395922A (en) 1995-03-07
DE69011853D1 (de) 1994-09-29
US5514585A (en) 1996-05-07
US5510249A (en) 1996-04-23
ES2062514T5 (es) 1998-06-01
CA2050336C (en) 2000-01-18
ES2062514T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
NO974899L (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
FI892881A (fi) Menetelmä terapeuttisesti käyttökelpoisten aminohappojohdannaisten va lmistamiseksi
NO175371C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminosyrederivater
NO167202C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (1h-imidazol-1-ylmetyl)-substituerte benzimidazolderivater.
NO167924C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive thymopentinanaloger
NO175100C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive 4(3H)-pteridinoner
NO175258C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 7-oksabicykloheptyl-substituerte heterocyklisk amidprostaglandinanaloger
NO903941D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-derivater.
NO177141C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminosyreantagonister
NO169963C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte 3,4-dihydro-2h-benzopyraner
FI871087A0 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
NO173503C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydroimidayo (1,4) benzodiazepin-2-tioner
NO155244C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituert-1,2-dihydro-3h-pyrrolo-(1,2-a)-pyrrol-1-carboxylsyrer fra deres tilsvarende nitriler.
NO882239D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive cykliske peptider.
NO177500C (no) Fremgangsmåte til fremstilling av en terapeutisk aktiv hirudinvariant
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
FI884660A0 (fi) Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi
ATE93526T1 (de) Peptide mit diaminoglycolen als uebergangszustandmimik.
NO173607C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive tienotriazolo-diazepin-derivater
NO167861C (no) Analogifremgangsmaate for fremstilling av en ny, terapeutisk aktiv indolokinolinforbindelse.
NO176105C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive peptidderivater
EP0352816A3 (en) Il-1alpha derivates and medicament for treating thrombocytopenia
IT7950629A0 (it) Procedimento per la preparazione di ossido di zirconio a partire da zirconato di calcio tecnico
NO164243C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive 16,17-acetalsubstituerte pregnan-21-oinsyrederivater